The metabolites of the manumycin family are known to have a broad range of antibiotic functions including antibacterial, anticoccidial, and antifungal activities (1). Manumycin compounds also display a strong activity against farnesyltransferase, IB kinase , interleukin-1-converting enzymes, and acetylcholinesterase and are considered as drug candidates to treat cancers, inflammation, and Alzheimer disease (1-4). Asukamycin A1, a manumycin-type metabolite, contains a unique 2-amino-4-hydroxy-5,6-epoxycyclohex-2-enone (mC 7 N) 3 core and two trans-triene polyketide chains, in which the upper one starts with a cyclohexane ring, and the lower one terminates in the five-membered ring of a 2-amino-3-hydroxycyclopent-2-enone (C 5 N) moiety (Fig.